List of patents in the Antibody industry

Patents where

Current Assignee

Industry

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 11534462 Antibody or antigen binding fragment thereof for specifically recognizing B cell malignancy, chimeric antigen receptor comprising same and use thereof	Patent 11534462 was granted and assigned to AbClon on December, 2022 by the United States Patent and Trademark Office.	AbClon	AbClon	United States Patent and Trademark Office	11534462	December 27, 2022
‌ US Patent 10303979 System and method for classifying and segmenting microscopy images with deep multiple instance learning	Patent 10303979 was granted and assigned to Phenomic AI on May, 2019 by the United States Patent and Trademark Office.		Phenomic AI	United States Patent and Trademark Office	10303979	May 28, 2019
‌ US Patent 11272695 Genetically modified non-human animal with human or chimeric PD-1	Patent 11272695 was granted and assigned to Biocytogen on March, 2022 by the United States Patent and Trademark Office.	Biocytogen	Biocytogen	United States Patent and Trademark Office	11272695	March 15, 2022
‌ US Patent 11407833 Anti-VISTA antibody and use thereof	Patent 11407833 was granted and assigned to PharmAbcine on August, 2022 by the United States Patent and Trademark Office.	PharmAbcine	PharmAbcine	United States Patent and Trademark Office	11407833	August 9, 2022
‌ US Patent 11317611 Genetically modified non-human animal with human or chimeric PD-L1		Biocytogen	Biocytogen	United States Patent and Trademark Office	11317611	May 3, 2022
‌ US Patent 9249219 Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof	Patent 9249219 was granted and assigned to PharmAbcine on February, 2016 by the United States Patent and Trademark Office.	PharmAbcine	PharmAbcine	United States Patent and Trademark Office	9249219	February 2, 2016
‌ US Patent 9249220 Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof	Patent 9249220 was granted and assigned to PharmAbcine on February, 2016 by the United States Patent and Trademark Office.	PharmAbcine	PharmAbcine	United States Patent and Trademark Office	9249220	February 2, 2016
‌ US Patent 10155817 Dual-target antibody targeting VEGFR-2 and DLL4 and pharmaceutical composition including same	Patent 10155817 was granted and assigned to PharmAbcine on December, 2018 by the United States Patent and Trademark Office.	PharmAbcine	PharmAbcine	United States Patent and Trademark Office	10155817	December 18, 2018
‌ US Patent 10314297 DNA knock-in system	Patent 10314297 was granted and assigned to Biocytogen on June, 2019 by the United States Patent and Trademark Office.	Biocytogen	Biocytogen	United States Patent and Trademark Office	10314297	June 11, 2019
‌ US Patent 10106622 Human antibody specific to c-Met and preparation method thereof	Patent 10106622 was granted and assigned to PharmAbcine on October, 2018 by the United States Patent and Trademark Office.	PharmAbcine	PharmAbcine	United States Patent and Trademark Office	10106622	October 23, 2018
‌ US Patent 11407834 Anti-PD-L1 antibody and use thereof	Patent 11407834 was granted and assigned to PharmAbcine on August, 2022 by the United States Patent and Trademark Office.	PharmAbcine	PharmAbcine	United States Patent and Trademark Office	11407834	August 9, 2022
‌ US Patent 11359016 Anti-CTLA4 antibodies and methods of making and using the same	Patent 11359016 was granted and assigned to Adagene on June, 2022 by the United States Patent and Trademark Office.	Adagene	Adagene	United States Patent and Trademark Office	11359016	June 14, 2022
‌ US Patent 11439132 Humanized transgenic animal		Biocytogen	Biocytogen	United States Patent and Trademark Office	11439132	September 13, 2022
‌ US Patent 11505806 Genetically modified non-human animal with human or chimeric OX40		Biocytogen	Biocytogen	United States Patent and Trademark Office	11505806	November 22, 2022
‌ US Patent 11534502 Genetically modified non-human animal with human or chimeric TIGIT	Patent 11534502 was granted and assigned to Biocytogen on December, 2022 by the United States Patent and Trademark Office.	Biocytogen	Biocytogen	United States Patent and Trademark Office	11534502	December 27, 2022
‌ US Patent 11352429 Anti-PD-1 antibodies and uses thereof	Patent 11352429 was granted and assigned to Biocytogen on June, 2022 by the United States Patent and Trademark Office.	Biocytogen	Biocytogen	United States Patent and Trademark Office	11352429	June 7, 2022
‌ US Patent 10925264 Genetically modified non-human animal with human or chimeric LAG-3	Patent 10925264 was granted and assigned to Biocytogen on February, 2021 by the United States Patent and Trademark Office.	Biocytogen	Biocytogen	United States Patent and Trademark Office	10925264	February 23, 2021
‌ US Patent 11350614 Genetically modified non-human animal with human or chimeric CD28		Biocytogen	Biocytogen	United States Patent and Trademark Office	11350614	June 7, 2022
‌ US Patent 11279948 Genetically modified non-human animal with human or chimeric OX40		Biocytogen	Biocytogen	United States Patent and Trademark Office	11279948	March 22, 2022
‌ US Patent 10912287 Genetically modified mice expressing humanized PD-1	Patent 10912287 was granted and assigned to Biocytogen on February, 2021 by the United States Patent and Trademark Office.	Biocytogen	Biocytogen	United States Patent and Trademark Office	10912287	February 9, 2021
‌ US Patent 11564381 Genetically modified non-human animal with human or chimeric LAG3			Biocytogen	United States Patent and Trademark Office	11564381	January 31, 2023
‌ US Patent 11464876 Genetically modified mouse comprising a chimeric TIGIT	Patent 11464876 was granted and assigned to Biocytogen on October, 2022 by the United States Patent and Trademark Office.	Biocytogen	Biocytogen	United States Patent and Trademark Office	11464876	October 11, 2022
‌ US Patent 11071290 Genetically modified non-human animal with human or chimeric CTLA-4	Patent 11071290 was granted and assigned to Biocytogen on July, 2021 by the United States Patent and Trademark Office.	Biocytogen	Biocytogen	United States Patent and Trademark Office	11071290	July 27, 2021
‌ US Patent 11497198 Genetically modified mice expressing humanized CD40	Patent 11497198 was granted and assigned to Biocytogen on November, 2022 by the United States Patent and Trademark Office.	Biocytogen	Biocytogen	United States Patent and Trademark Office	11497198	November 15, 2022
‌ US Patent 10174116 Antibody specifically binding to HER2	Patent 10174116 was granted and assigned to AbClon on January, 2019 by the United States Patent and Trademark Office.	AbClon	AbClon	United States Patent and Trademark Office	10174116	January 8, 2019

Results per page:

56 results

0 selected

56 results

0 selected